Aragen Launches CHOMax™, an Accelerated Platform for DNA to IND-Enabling Clinical Supply in ~10 MonthsAccelerated pathway: ...
Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 ...
Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback